SCHEMBL17865261

SCHEMBL17865261

Cn1nccc1C(O)c1cnccc1C(F)(F)F

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 1/20 0.40
SYK P43405 1/20 0.39
SCD O00767 1/20 0.33
SCD5 Q86SK9 1/20 0.33
RBP4 P02753 1/20 0.32
ALDH1A1 P00352 1/20 0.32
S1PR1 P21453 2/20 0.32
S1PR3 Q99500 2/20 0.32
CYP11B2 P19099 2/20 0.32
TRPA1 O75762 1/20 0.32
OPRM1 P35372 1/20 0.31
KCNH2 Q12809 1/20 0.31
SIGMAR1 Q99720 1/20 0.31
NPC1 O15118 1/20 0.31
POLB P06746 1/20 0.31
TRPM8 Q7Z2W7 1/20 0.31
SSTR4 P31391 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8327409 0.81 NPC1 (0.38) RBP4ALDH1A1CYP11B2NPC1POLB
SCHEMBL19735056 0.81 GAA (0.39) SYKALDH1A1
SCHEMBL332464 0.78 SYK (0.36) SYK
SCHEMBL17865256 0.73 SYK (0.39) SYKALDH1A1OPRM1KCNH2SIGMAR1
SCHEMBL6153433 0.72 PDE2A (0.44) SCDSCD5RBP4ALDH1A1S1PR1
SCHEMBL17865259 0.72 CYP3A4 (0.42) CYP11B2KCNH2
SCHEMBL29435625 0.71 RPS6KA3 (0.39) SCDSCD5ALDH1A1S1PR1TRPA1
SCHEMBL12029013 0.71 RPS6KA3 (0.39) SCDSCD5ALDH1A1S1PR1TRPA1
SCHEMBL17865251 0.70 SYK (0.43) SYK
SCHEMBL17865253 0.70 SYK (0.39) LRRK2SYKALDH1A1NPC1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10189828-B2 1-methylpyrazole-piperazine compounds having multimodal activity against pain LABORATORIOS DEL DR. ESTEVE S.A. (ES) 2019-01-29 US disclosed
US-10189828-B2 1-methylpyrazole-piperazine compounds having multimodal activity against pain LABORATORIOS DEL DR. ESTEVE S.A. (ES) 2019-01-29 US disclosed
US-20170362215-A1 1-METHYLPYRAZOLE-PIPERAZINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN ESTEVE PHARMACEUTICALS, S.A. (ES) 2017-12-21 US disclosed
US-20170362215-A1 1-METHYLPYRAZOLE-PIPERAZINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN ESTEVE PHARMACEUTICALS, S.A. (ES) 2017-12-21 US disclosed
WO-2016096126-A1 1-METHYLPYRAZOLE-PIPERAZINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2016-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170362215-A1 1-METHYLPYRAZOLE-PIPERAZINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN OPRD1, OPRM1, SIGMAR1 LRRK2 4203/4885SYK 1389/4885SCD 3260/4885
US-10189828-B2 1-methylpyrazole-piperazine compounds having multimodal activity against pain OPRD1, OPRM1, SIGMAR1 LRRK2 4203/4885SYK 1389/4885SCD 3260/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.